ArticleWorld journal of clinical cases2026
Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis - the importance of structured causality assessment: A case report.
Article in World journal of clinical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-induced liver injury poses a diagnostic challenge in oncology patients, especially those on immune checkpoint inhibitors, because symptoms often overlap with immune-mediated hepatitis. The increasing use of social media has led people to self-administer veterinary anthelmintics like fenbendazole for cancer, often at high doses and without medical guidance, despite limited data on safety or effectiveness. CASE SUMMARY: We report a case of a 47-year-old woman with metastatic colon cancer on nivolumab/relatlimab who developed severe hepatocellular liver injury after increasing her self-administered dose of fenbendazole. A detailed medical and temporal history, supported by a Roussel Uclaf Causality Assessment Method score of 8 (probable), identified fenbendazole as the most likely cause. Rapid biochemical improvement occurred after stopping the drug, with safe reintroduction of immunotherapy and no recurrence of liver injury.
conclusionThis case emphasizes the importance of thorough medication history-taking and structured causality assessment to distinguish between unregulated drug-induced liver injury and immune-related adverse events in cancer care. The use of social media to promote alternative therapies necessitates proactive patient counseling due to significant liver risks, and careful diagnostic evaluation can prevent unnecessary immunosuppression or treatment delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.